Penumbra Reports Mixed Q1 Results Amidst Pending Acquisition, Executives Terminate 10b5-1 Plans
PEN sits 47% above its 52-week low of $221.26.
Summary
Penumbra reported Q1 2026 revenue growth of 15.6% to $374.8 million, but net income fell 17.0% due to increased acquisition-related expenses, while confirming its pending $14.5 billion acquisition by Boston Scientific and disclosing the termination of executive 10b5-1 trading plans.
Key Events · Earnings and Guidance · PEN
-
Q1 2026 Financial Results Show Mixed Performance
Revenue increased 15.6% year-over-year to $374.8 million, driven by strong sales of thrombectomy and embolization/access products. However, net income decreased 17.0% to $32.6 million, primarily due to a 25.6% rise in sales, general, and administrative (SG&A) expenses, which included $9.4 million in acquisition-related costs.
-
Pending Acquisition by Boston Scientific Reaffirmed
The company reiterated its definitive merger agreement with Boston Scientific Corporation, valuing each share at $374, with consideration split approximately 73% cash and 27% stock. The transaction, previously announced, is expected to close in 2026, subject to customary approvals.
-
Executive 10b5-1 Trading Plans Terminated
The CEO, a Director, and the Executive Vice President/General Counsel terminated their Rule 10b5-1 trading plans during Q1 2026. Notably, no shares were sold under these plans prior to their termination, indicating a shift in their pre-planned selling strategies, likely influenced by the pending merger.
-
Share Repurchase Program Extended
The company has remaining authority to repurchase $100.0 million of its common stock under a program extended to December 31, 2026. This program's relevance is diminished by the pending acquisition.
Analysis · PEN · Industrial Applications And Services
This quarterly report provides an important update on Penumbra's financial performance as it progresses towards its acquisition by Boston Scientific. While the company demonstrated strong top-line growth with a 15.6% increase in revenue, profitability was impacted by a 17.0% decline in net income, largely attributable to a significant rise in sales, general, and administrative expenses, including $9.4 million in acquisition-related costs. The reiteration of the $14.5 billion merger agreement, with a $374 per share valuation, provides crucial context for investors, especially given the current stock price trades below the offer. The termination of Rule 10b5-1 trading plans by the CEO and other key executives, without any shares being sold, is a notable development, likely a procedural adjustment in light of the pending merger. Investors should monitor the progress of the acquisition and its impact on future financial disclosures.
At the time of this filing, PEN was trading at $324.19 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $12.7B. The 52-week trading range was $221.26 to $362.41. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.